MedRhythms: A Symphony of Innovation and Leadership in Neurotechnology

The convergence of music, technology, and neuroscience is reshaping the future of healthcare, and MedRhythms stands at the forefront of this revolution. With its FDA-cleared therapies InTandem® and Movive™, the company is addressing critical unmet needs in mobility rehabilitation for stroke and Parkinson's disease patients. But its recent leadership transition—bringing in Larry Jasinski, a veteran of scaling neurotech companies—adds a critical layer of strategic execution to its scientific vision. This combination of proven leadership, regulatory triumphs, and a first-of-its-kind partnership with Universal Music Group (UMG) positions MedRhythms as a prime investment opportunity in a rapidly growing market.

The Leadership Pivot: Jasinski's Track Record Meets Harris's Science

In July 2025, MedRhythms announced a strategic leadership shift: co-founder Brian Harris transitioned to Chief Scientific Officer (CSO), while Larry Jasinski, former CEO of Lifeward (NASDAQ: LFWD), took the helm as CEO. This move is a masterstroke. Jasinski's tenure at Lifeward, where he led the IPO of a spinal cord injury exoskeleton company and secured national reimbursement, offers a blueprint for scaling neurotech businesses. His ability to navigate FDA clearances, CMS reimbursement, and market adoption—key to Lifeward's success—is now focused squarely on MedRhythms.

Meanwhile, Harris's transition to CSO ensures MedRhythms retains its scientific rigor. As the architect of its proprietary Rhythmic Auditory Stimulation (RAS) platform, Harris's expertise is critical to advancing therapies for Parkinson's, stroke, and other neurological conditions. The pairing of Jasinski's commercial acumen with Harris's clinical depth creates a rare synergy in a sector often split between innovators and operators.

FDA-Cleared Therapies: The Science of Sound

MedRhythms' therapies leverage RAS, a decades-old neuroscience principle that uses music to entrain neural circuits, improving gait and motor function. InTandem® (for stroke) and Movive™ (for Parkinson's) are Class II FDA-cleared devices, with Movive™ launching in Q2 2025. Both systems combine wearable sensors, adaptive algorithms, and individually curated music playlists to deliver personalized therapy.

The clinical case is compelling:
- InTandem® improved gait speed by 22% in chronic stroke patients in a pivotal trial, reducing fall risks and enhancing mobility.
- Movive™ targets Parkinson's gait freezing, a symptom affecting 80% of patients, with early data showing significant functional gains.

Crucially, these therapies are home-based, addressing a critical gap in neurorehabilitation. Traditional outpatient therapy is limited in frequency and accessibility, while MedRhythms' systems allow daily use, maximizing patient adherence.

CMS Coverage: Unlocking Medicare's $1.3 Trillion

MedRhythms' success hinges on reimbursement. In January 2025, CMS finalized coverage for InTandem® under HCPCS code E3200, classifying it as durable medical equipment (DME) with monthly Medicare payments tied to commercial pricing. This decision opens access to 15 million Medicare beneficiaries, including 800,000 chronic stroke patients and 110,000 veterans with Parkinson's.

The implications are vast:
- Margin Boost: DME reimbursement typically offers higher margins than traditional therapies, as MedRhythms retains control over pricing.
- Scalability: With CMS coverage in place, MedRhythms can partner with home health providers to distribute its systems nationwide, avoiding the fragmented clinic-based model.

Movive™'s pending CMS coverage—likely following InTandem's path—will further expand the addressable market. Combined, stroke and Parkinson's mobility therapies represent a $3.2 billion opportunity in the U.S. alone.

The UMG Partnership: Music as Medicine

MedRhythms' collaboration with Universal Music Group (UMG) is its secret weapon. UMG's catalog provides access to culturally resonant music, which research shows boosts patient engagement by 30–40%. The partnership also includes data analytics and marketing support, enabling MedRhythms to tailor therapy playlists to individual preferences.

This isn't just about making rehab more enjoyable. Music's ability to activate reward pathways in the brain enhances neuroplasticity, making RAS more effective. The result? A therapy that's both scientifically validated and emotionally compelling—a rare combination in healthcare.

Risks and Considerations

• Regulatory Delays: Movive™'s CMS coverage timeline could slip, though InTandem's precedent offers optimism.
• Market Competition: Rival digital therapeutics may emerge, though MedRhythms' FDA clearances and UMG partnership create high barriers.
• Execution Risk: Scaling home-based distribution requires logistical precision, but Jasinski's track record suggests he's up to the challenge.

Why Invest Now?

MedRhythms is at an inflection point. With FDA clearances secured, CMS reimbursement in place, and a leadership team proven to scale neurotech businesses, it's poised to capture a large slice of the mobility rehab market. Key catalysts in 2025–2026 include:
1. Movive™ Launch: Q2 2025 rollout to Parkinson's patients, leveraging Harris's clinical expertise.
2. CMS Expansion: Potential coverage for additional indications, such as multiple sclerosis.
3. Partnership Synergy: UMG's music catalog and marketing support could accelerate adoption.

For investors, MedRhythms offers exposure to two secular trends: the rise of digital therapeutics and the aging population's demand for mobility solutions. With strong margins, a defensible IP portfolio, and a leadership team that's done this before, MedRhythms is a rare neurotech gem.

Conclusion: A Symphony of Growth

MedRhythms is more than a company—it's a paradigm shift. By merging music with medicine, it's addressing a $3.2 billion market with therapies that are both clinically effective and emotionally resonant. Jasinski's leadership and Harris's science form an unstoppable duo, while CMS coverage and UMG's partnership provide the fuel for exponential growth.

In a sector crowded with me-too apps and devices, MedRhythms stands out. Its combination of FDA validation, reimbursement clarity, and first-mover advantage in music-based neurorehabilitation makes it a compelling investment. For those willing to bet on innovation that truly changes lives, MedRhythms is the crescendo of neurotech's future.